Italia markets closed

Blueprint Medicines Corporation (0HOJ.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
43,34-0,06 (-0,13%)
Alla chiusura: 02:30PM GMT
Schermo intero
Chiusura precedente43,40
Aperto0,00
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume11.390
Media VolumeN/D
Capitalizzazione21,022M
Beta (5 anni mensile)0,66
Rapporto PE (ttm)N/D
EPS (ttm)-11,06
Prossima data utili14 feb 2023 - 20 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

    Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based m